We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+1.21%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.9B
AUM Growth
-$88M
Cap. Flow
-$194M
Cap. Flow %
-10.24%
Top 10 Hldgs %
47.92%
Holding
151
New
44
Increased
37
Reduced
36
Closed
31
Avg Time Held Equity + Options
1 year
Top 10 Avg Time Held Equity + Options
1.5 years
Top 20 Avg Time Held Equity + Options
1.1 years
Avg Time Held Equity only
1.1 years
Top 10 Avg Time Held Equity only
1.2 years
Top 20 Avg Time Held Equity only
1 year

Top Buys

Rank Stock Value
1
BKD icon
Brookdale Senior Living
BKD
+$44.7M
2
WELL icon
Welltower
WELL
+$35.8M
3
DOC icon
Healthpeak Properties
DOC
+$33.9M
4
ABVX icon
Abivax
ABVX
+$32.7M
5
OHI icon
Omega Healthcare
OHI
+$26.7M

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$48.5M
2
DHR icon
Danaher
DHR
+$42.6M
3
VERA icon
Vera Therapeutics
VERA
+$38.7M
4
VRDN icon
Viridian Therapeutics
VRDN
+$31.7M
5
BRKR icon
Bruker
BRKR
+$27.9M

Sector Composition

Rank Sector Weight
1 Healthcare 74.35%
2 Miscellaneous 20.04%
3 Real Estate 5.59%
4 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ENSG icon
76
The Ensign Group
ENSG
$10.3B
$2.97M 0.16%
+14,761
New +$2.89M
2026 Q1
0 quarters
IVVD icon
77
Invivyd
IVVD
$183M
$2.96M 0.16%
2,276,349
+136,219
+6% +$250K
2025 Q3
2 quarters
PMVP icon
78
PMV Pharmaceuticals
PMVP
$66.8M
$2.91M 0.15%
+2,348,360
New +$2.99M
2026 Q1
0 quarters
ALEC icon
79
Alector
ALEC
$212M
$2.9M 0.15%
1,351,106
+344,943
+34% +$693K
2024 Q1
8 quarters
ANRO icon
80
Alto Neuroscience
ANRO
$871M
$2.81M 0.15%
+125,168
New +$2.32M
2026 Q1
0 quarters
RLAY icon
81
Relay Therapeutics
RLAY
$3.62B
$2.69M 0.14%
270,705
-218,432
-45% -$1.95M
2025 Q2
3 quarters
REPL icon
82
Replimune Group
REPL
$1.03B
$2.56M 0.14%
+334,861
New +$2.56M
2026 Q1
0 quarters
LBRX icon
83
LB Pharmaceuticals
LBRX
$1.17B
$2.47M 0.13%
+100,198
New +$2.31M
2026 Q1
0 quarters
LPCN icon
84
Lipocine
LPCN
$12.5M
$2.36M 0.12%
+294,989
New +$2.57M
2026 Q1
0 quarters
VIR icon
85
Vir Biotechnology
VIR
$1.69B
$2.24M 0.12%
+250,000
New +$1.99M
2026 Q1
0 quarters
AVR icon
86
Anteris Technologies
AVR
$596M
$2.23M 0.12%
401,187
-98,813
-20% -$568K
2025 Q3
2 quarters
AMRN icon
87
Amarin Corp
AMRN
$238M
$2.14M 0.11%
147,715
-24,473
-14% -$366K
2018 Q1
32 quarters
SVRA icon
88
Savara
SVRA
$931M
$2.1M 0.11%
384,264
+214,069
+126% +$1.19M
2025 Q4
1 quarter
RLMD icon
89
Relmada Therapeutics
RLMD
$334M
$1.93M 0.1%
+277,899
New +$1.31M
2026 Q1
0 quarters
CTNM icon
90
Contineum Therapeutics
CTNM
$266M
$1.91M 0.1%
146,411
+8,918
+6% +$120K
2025 Q3
2 quarters
STRO icon
91
Sutro Biopharma
STRO
$182M
$1.82M 0.1%
73,161
-120,410
-62% -$2.18M
2023 Q2
11 quarters
INO icon
92
Inovio Pharmaceuticals
INO
$104M
$1.8M 0.1%
+1,035,360
New +$1.7M
2026 Q1
0 quarters
SRZN icon
93
Surrozen
SRZN
$277M
$1.71M 0.09%
58,624
-36,662
-38% -$879K
2025 Q3
2 quarters
IFRX icon
94
InflaRx
IFRX
$199M
$1.57M 0.08%
1,758,573
+1,261
+0.1% +$1.19K
2023 Q2
11 quarters
KPTI icon
95
Karyopharm Therapeutics
KPTI
$7.94M
$1.54M 0.08%
+276,174
New +$2.11M
2026 Q1
0 quarters
ANAB icon
96
AnaptysBio
ANAB
$1.42B
$1.5M 0.08%
27,089
-93,838
-78% -$5.05M
2025 Q4
1 quarter
NVCR icon
97
NovoCure
NVCR
$1.62B
$1.47M 0.08%
134,917
+13,939
+12% +$174K
2025 Q4
1 quarter
BVS icon
98
Bioventus
BVS
$913M
$1.45M 0.08%
159,110
-312,147
-66% -$2.62M
2025 Q3
2 quarters
AGL icon
99
Agilon Health
AGL
$1.45B
$1.4M 0.07%
+176,588
New +$2.86M
2026 Q1
0 quarters
RARE icon
100
Ultragenyx Pharmaceutical
RARE
$1.44B
$1.31M 0.07%
62,575
-254,607
-80% -$5.73M
2025 Q4
1 quarter
2 3
4
5 6

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Eversept Partners held 151 positions worth $1.9B, down 4.4% from $1.98B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Eversept Partners withdrew a net $194M in Q1 2026, closing 31 positions and reducing 36 holdings. Its most notable exit was Danaher, an estimated $42.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 90% a quarter earlier, followed by Miscellaneous and Real Estate.

Against the trend, Eversept Partners opened a new position in Welltower worth $35.8M.

  • Eversept Partners's largest Q1 2026 buy was Welltower: 180,953 shares worth $35.8M.
  • Eversept Partners added most to Brookdale Senior Living in Q1 2026, an estimated $44.7M increase.
  • Eversept Partners's biggest Q1 2026 reduction was GSK, cutting an estimated $48.5M.
  • Eversept Partners fully exited Danaher in Q1 2026, selling an estimated $42.6M.
  • Eversept Partners's ten largest holdings make up 48% of its $1.9B portfolio in Q1 2026.
  • Eversept Partners opened 44 new positions and closed 31 in Q1 2026.
  • Eversept Partners's portfolio value fell 4.4% quarter-over-quarter to $1.9B.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.